Rigel Pharmaceuticals, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Cover
- DOCUMENT AND ENTITY INFORMATION
Financial Statements
Notes to Financial Statements
Accounting Policies
- SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)
Notes Tables
Notes Details

SUBSEQUENT EVENT (Details)

v3.10.0.1

SUBSEQUENT EVENT (Details) - Grifols - Subsequent events - Commercialization license agreement $ in Millions	1 Months Ended
	Jan. 31, 2019 USD ($)
Subsequent Event [Line Items]
Upfront payment received	$ 30.0
Contingent acquisition one-time agreement termination payment	$ 60.0
Prior written notice following the second anniversary of the first MAA approval of fostamatinib in Europe and Turkey
Subsequent Event [Line Items]
Notice period for termination of agreement	18 months
Right to terminate agreement within number of months after second anniversary	6 months
Terminated agreement upon prior written notice within six months after second anniversary of agreement
Subsequent Event [Line Items]
Notice period for termination of agreement	60 days
Contingent upfront fee, refund requirement	$ 25.0
Maximum \| fostamatinib
Subsequent Event [Line Items]
Royalty payment as a percentage of net sales	30.00%
Commercial Milestones
Subsequent Event [Line Items]
Contingent payments	$ 297.5
EMA approval of fostamatinib for treatment of chronic ITP \| fostamatinib
Subsequent Event [Line Items]
Contingent payments	17.5
EMA approval of fostamatinib \| fostamatinib
Subsequent Event [Line Items]
Contingent payments	$ 2.5

- Definition

Represents the contingent amount of upfront fee refund requirement under certain terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementContingentUpfrontFeeRefundRequirement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the notice period for termination of agreement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementNoticePeriodForTerminationOfAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the right to terminate agreement within number of months after the second anniversary, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementRightToTerminateAgreementWithinNumberOfMonthsAfterSecondAnniversary
Namespace Prefix:	rigl_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement.

+ References

No definition available.

+ Details

Name:	rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the contingent acquisition one-time agreement termination payment.

+ References

No definition available.

+ Details

Name:	rigl_ContingentAcquisitionOneTimeAgreementTerminationPayment
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents additional contingent payments by entities.

+ References

No definition available.

+ Details

Name:	rigl_ContingentPaymentsUnderAgreement
Namespace Prefix:	rigl_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents royalty payment as a percentage of net sales.

+ References

No definition available.

+ Details

Name:	rigl_RoyaltyPaymentAsPercentageOfNetSales
Namespace Prefix:	rigl_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	dei_LegalEntityAxis=rigl_GrifolsS.a.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=rigl_CommercializationLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=rigl_PriorWrittenNoticeFollowingSecondAnniversaryOfFirstMaaApprovalOfFostamatinibInEuropeAndTurkeyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=rigl_PriorWrittenNoticeWithinSixMonthsAfterSecondAnniversaryOfAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=rigl_FostamatinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: